Samaritan Pharma (AMEX:LIV) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Samaritan Pharma (AMEX:LIV)

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Larry Dambra who started this subject	8/31/2004 11:29:31 AM
From: Larry Dambra	of 3

Company Profile from BusinessWire as of 8/27/04 Samaritan Pharmaceuticals is working to ensure a longer and better life, for patients suffering with AIDS, Alzheimer's, cancer and cardiovascular disease. Samaritan is an innovation-driven biopharmaceutical, with a clear focus on advancing innovative drugs through clinical development to become commercially valuable compounds. Samaritan has in-licensed 12 innovations from Georgetown University and is concurrently advancing four drug programs: SP-01A (HIV) clinical trials; SP-10 (HIV) preIND status; SP-233 (Alzheimer's) preIND status; and SP-1000 (cardiovascular) animal studies; along with an STTR NIH grant to develop a simple blood test to diagnose Alzheimer's. Samaritan's proprietary HIV drug SP-01A is the closest to commercialization. SP-01A appears to be an oral, "Entry Inhibitor" drug that works by blocking the HIV virus' ability to infect a cell. Encouraging data from its FDA Phase I/II trial, suggests SP-01A as a promising drug for patients experiencing "drug resistance."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext